Rituximab as first-line treatment of pemphigus

Enno Schmidt

doi:10.1016/S0140-6736(17)30787-0

Rituximab as first-line treatment of pemphigus

Department of Dermatology, Allergology and Venereology

Original language	English
Journal	The Lancet
Volume	389
Issue number	10083
Pages (from-to)	1956-1958
Number of pages	3
ISSN	0140-6736
DOIs	https://doi.org/10.1016/S0140-6736(17)30787-0
Publication status	Published - 20.05.2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Access to Document

10.1016/S0140-6736(17)30787-0

Cite this

@article{05b64f59e2d04c6880a3f6015846a192,

title = "Rituximab as first-line treatment of pemphigus",

author = "Enno Schmidt",

year = "2017",

month = may,

day = "20",

doi = "10.1016/S0140-6736(17)30787-0",

language = "English",

volume = "389",

pages = "1956--1958",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10083",

}

TY - JOUR

T1 - Rituximab as first-line treatment of pemphigus

AU - Schmidt, Enno

PY - 2017/5/20

Y1 - 2017/5/20

UR - https://www.scopus.com/pages/publications/85016056878

U2 - 10.1016/S0140-6736(17)30787-0

DO - 10.1016/S0140-6736(17)30787-0

M3 - Comments/Debates

C2 - 28342636

AN - SCOPUS:85016056878

SN - 0140-6736

VL - 389

SP - 1956

EP - 1958

JO - The Lancet

JF - The Lancet

IS - 10083

ER -

Rituximab as first-line treatment of pemphigus

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Cite this